MA54940A - Dérivés d'acides aminés pour le traitement de maladies inflammatoires - Google Patents
Dérivés d'acides aminés pour le traitement de maladies inflammatoiresInfo
- Publication number
- MA54940A MA54940A MA054940A MA54940A MA54940A MA 54940 A MA54940 A MA 54940A MA 054940 A MA054940 A MA 054940A MA 54940 A MA54940 A MA 54940A MA 54940 A MA54940 A MA 54940A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- amino acid
- acid derivatives
- inflammatory diseases
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962795549P | 2019-01-22 | 2019-01-22 | |
| US201962871951P | 2019-07-09 | 2019-07-09 | |
| PCT/US2020/014636 WO2020154420A2 (fr) | 2019-01-22 | 2020-01-22 | Dérivés d'acides aminés pour le traitement de maladies inflammatoires |
| EP20708296.7A EP3924349B1 (fr) | 2019-01-22 | 2020-01-22 | Dérivés d'acides aminés pour le traitement de maladies inflammatoires |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54940A true MA54940A (fr) | 2021-12-22 |
| MA54940B1 MA54940B1 (fr) | 2025-09-30 |
Family
ID=69726748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54940A MA54940B1 (fr) | 2019-01-22 | 2020-01-22 | Dérivés d'acides aminés pour le traitement de maladies inflammatoires |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20220081415A1 (fr) |
| EP (1) | EP3924349B1 (fr) |
| JP (2) | JP7784708B2 (fr) |
| KR (1) | KR20210141930A (fr) |
| CN (1) | CN113614074A (fr) |
| AU (2) | AU2020211980B2 (fr) |
| BR (1) | BR112021014372A2 (fr) |
| CA (1) | CA3127246A1 (fr) |
| CL (1) | CL2021001944A1 (fr) |
| CO (1) | CO2021010931A2 (fr) |
| DK (1) | DK3924349T3 (fr) |
| EC (1) | ECSP21062210A (fr) |
| ES (1) | ES3038582T3 (fr) |
| FI (1) | FI3924349T3 (fr) |
| HR (1) | HRP20251058T1 (fr) |
| HU (1) | HUE072722T2 (fr) |
| IL (1) | IL284980B1 (fr) |
| LT (1) | LT3924349T (fr) |
| MA (1) | MA54940B1 (fr) |
| MD (1) | MD3924349T2 (fr) |
| MX (1) | MX2021008748A (fr) |
| PH (1) | PH12021551760A1 (fr) |
| PL (1) | PL3924349T3 (fr) |
| PT (1) | PT3924349T (fr) |
| RS (1) | RS67095B1 (fr) |
| SG (1) | SG11202107977TA (fr) |
| SI (1) | SI3924349T1 (fr) |
| SM (1) | SMT202500289T1 (fr) |
| WO (1) | WO2020154420A2 (fr) |
| ZA (1) | ZA202105229B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019389168A1 (en) | 2018-11-30 | 2021-06-24 | Comet Therapeutics, Inc. | Pantetheine derivatives and uses thereof |
| AU2024411297A1 (en) | 2023-12-24 | 2026-07-23 | Alkapharmics | Potent nf-kb inhibitors for the treatment of inflammatory diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| WO1999011658A1 (fr) * | 1997-08-29 | 1999-03-11 | Proteus Molecular Design Ltd. | Derives de meta-benzamidine comme inhibiteurs de serine protease |
| US6218390B1 (en) * | 1998-12-17 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Morpholinone and morpholine derivatives and uses thereof |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8710069B2 (en) * | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-nornicotine codrugs combinations for pain management |
| EP2331499B1 (fr) * | 2008-08-19 | 2016-09-21 | Janssen Pharmaceutica NV | Antagonistes des récepteurs au froid activés par le menthol |
| WO2010127058A1 (fr) * | 2009-05-01 | 2010-11-04 | Profectus Biosciences, Inc. | Dérivés de benzamide et de naphtamide inhibant le facteur nucléaire kappa(b) (nf-kb) |
-
2020
- 2020-01-22 PT PT207082967T patent/PT3924349T/pt unknown
- 2020-01-22 SI SI202030657T patent/SI3924349T1/sl unknown
- 2020-01-22 CA CA3127246A patent/CA3127246A1/fr active Pending
- 2020-01-22 US US17/424,455 patent/US20220081415A1/en active Pending
- 2020-01-22 HR HRP20251058TT patent/HRP20251058T1/hr unknown
- 2020-01-22 CN CN202080021880.4A patent/CN113614074A/zh active Pending
- 2020-01-22 WO PCT/US2020/014636 patent/WO2020154420A2/fr not_active Ceased
- 2020-01-22 BR BR112021014372-6A patent/BR112021014372A2/pt unknown
- 2020-01-22 MX MX2021008748A patent/MX2021008748A/es unknown
- 2020-01-22 MA MA54940A patent/MA54940B1/fr unknown
- 2020-01-22 JP JP2021543302A patent/JP7784708B2/ja active Active
- 2020-01-22 LT LTEPPCT/US2020/014636T patent/LT3924349T/lt unknown
- 2020-01-22 AU AU2020211980A patent/AU2020211980B2/en active Active
- 2020-01-22 RS RS20250796A patent/RS67095B1/sr unknown
- 2020-01-22 FI FIEP20708296.7T patent/FI3924349T3/fi active
- 2020-01-22 ES ES20708296T patent/ES3038582T3/es active Active
- 2020-01-22 PL PL20708296.7T patent/PL3924349T3/pl unknown
- 2020-01-22 DK DK20708296.7T patent/DK3924349T3/da active
- 2020-01-22 MD MDE20211218T patent/MD3924349T2/ro unknown
- 2020-01-22 SM SM20250289T patent/SMT202500289T1/it unknown
- 2020-01-22 SG SG11202107977TA patent/SG11202107977TA/en unknown
- 2020-01-22 EP EP20708296.7A patent/EP3924349B1/fr active Active
- 2020-01-22 KR KR1020217026302A patent/KR20210141930A/ko active Pending
- 2020-01-22 PH PH1/2021/551760A patent/PH12021551760A1/en unknown
- 2020-01-22 IL IL284980A patent/IL284980B1/en unknown
- 2020-01-22 HU HUE20708296A patent/HUE072722T2/hu unknown
-
2021
- 2021-07-22 CL CL2021001944A patent/CL2021001944A1/es unknown
- 2021-07-23 ZA ZA2021/05229A patent/ZA202105229B/en unknown
- 2021-08-19 CO CONC2021/0010931A patent/CO2021010931A2/es unknown
- 2021-08-20 EC ECSENADI202162210A patent/ECSP21062210A/es unknown
-
2025
- 2025-01-31 JP JP2025014903A patent/JP2025062004A/ja active Pending
- 2025-12-18 AU AU2025283544A patent/AU2025283544A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3952902A4 (fr) | Formes posologiques et schémas de traitement pour des composés d'acides aminés | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MA56019A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA55560A (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| EP3866781A4 (fr) | Nouvelles compositions pour le traitement de maladies inflammatoires | |
| MA55604A (fr) | Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra | |
| MA50763A (fr) | Compositions d'acides aminés et méthodés de traitement de maladies et troubles musculaires | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| EP3820537A4 (fr) | Vecteurs de thérapie génique pour le traitement de la maladie de danon | |
| MX2018005694A (es) | 2- (1h-indazol-3-il) -3h-imidazo[4,5-c] piridinas y usos antiinflamatorios de las mismas. | |
| EP4045037C0 (fr) | Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1 | |
| MA51524A (fr) | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| EP3829569A4 (fr) | Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex | |
| MA49906A (fr) | Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3866777A4 (fr) | Polythérapie pour le traitement de maladies inflammatoires | |
| EP3934646A4 (fr) | Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| EP3649256A4 (fr) | Procédés de traitement d'une inflammation et de maladies et troubles associés par inhibition de la protéine kinase alpha 1 | |
| EP3593803A4 (fr) | Composés destinés au traitement de maladies causées par l'accumulation d'oxalate | |
| EP3877383A4 (fr) | Composés et compositions pour le traitement de maladies respiratoires | |
| EP4073060A4 (fr) | Inhibiteurs de l'histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs | |
| EP3766503A4 (fr) | Application d'un inhibiteur de micro-arn-210 dans la préparation de médicaments destinés au traitement de maladies cutanées inflammatoires |